Stock A291650 APTAMER SCIENCES INC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aptamer Sciences Inc

Equities

A291650

KR7291650000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-09 EDT 		5-day change 1st Jan Change
2,770 KRW -1.95% Intraday chart for Aptamer Sciences Inc -2.29% -23.16%
03-26 Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201 CI
2022 Aptamer Sciences Inc announced that it has received KRW 16.5 billion in funding from a group of investors CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 228,585 144,347 74,289 61,214
Enterprise Value (EV) 1 193,838 120,245 45,823 45,710
P/E ratio -26.4 x -18.8 x -10.4 x -4.5 x
Yield - - - -
Capitalization / Revenue 1,000 x 536 x 207 x 252 x
EV / Revenue 848 x 447 x 128 x 188 x
EV / EBITDA -54.2 x -33.1 x -5.86 x -3.92 x
EV / FCF -78.1 x -12.6 x -9.06 x -18.6 x
FCF Yield -1.28% -7.91% -11% -5.37%
Price to Book 6.54 x 4.62 x 2.56 x 4.08 x
Nbr of stocks (in thousands) 16,932 16,932 16,980 16,980
Reference price 2 13,500 8,525 4,375 3,605
Announcement Date 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 228.5 269.3 358.3 243.2
EBITDA 1 -3,575 -3,628 -7,821 -11,654
EBIT 1 -3,923 -4,067 -8,320 -12,207
Operating Margin -1,716.79% -1,510.39% -2,322.35% -5,019.47%
Earnings before Tax (EBT) 1 -3,843 -3,831 -8,301 -13,602
Net income 1 -3,843 -3,831 -7,116 -13,602
Net margin -1,681.97% -1,422.73% -1,986.19% -5,593.04%
EPS 2 -511.2 -452.5 -419.4 -801.0
Free Cash Flow 1 -2,482 -9,515 -5,055 -2,455
FCF margin -1,086.23% -3,533.66% -1,411.03% -1,009.64%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 34,747 24,103 28,466 15,504
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 -2,482 -9,515 -5,055 -2,455
ROE (net income / shareholders' equity) -18.2% -11.5% -23.5% -60.9%
ROA (Net income/ Total Assets) -10.8% -7.24% -13.2% -19.5%
Assets 1 35,469 52,897 53,988 69,692
Book Value Per Share 2 2,064 1,844 1,707 884.0
Cash Flow per Share 2 275.0 59.60 72.00 72.90
Capex 1 349 7,081 309 297
Capex / Sales 152.89% 2,629.62% 86.22% 122.19%
Announcement Date 21-03-01 22-03-01 23-03-01 24-02-29
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
APTAMER SCIENCES INC Stock Aptamer Sciences Inc
-23.16% 34.34M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A291650 Stock
  4. Financials Aptamer Sciences Inc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW